Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trials


Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas.

In the two phase III randomized, multi-center, placebo-controlled, double blind trials (EV001 and EV002), the composite endpoint required both the investigator and the study subject to independently agree that there had been at least a 2-point improvement 30 days after treatment when compared to baseline (pre-treatment). The responder rate for DWP-450 was 67.5% in the EV001 study and 70.4% in the EV002 study and both studies were statistically superior to their respective placebo control groups.

Chris Marmo, President of Beauty for ALPHAEON, said, "The results of our phase III clinical trials marks a significant milestone for ALPHAEON. It's a great advancement in the regulatory process and we look forward to leveraging our unique and innovative social commerce platform to offer this product to board certified specialty physicians."

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free